Government-Owned Inventions; Availability for Licensing, 37586-37587 [06-5882]

Download as PDF 37586 Federal Register / Vol. 71, No. 126 / Friday, June 30, 2006 / Notices instruments, contact Dr. Linda Kupfer, Fogarty International Center, National Institutes of Health, 16 Center Drive, Building 16, Bethesda, MD 20892–6705 or call non-toll-free number 301–496– 3288 or e-mail your request, including your address to kupferl@mail.nih.gov. Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication. Dated: June 21, 2006. Richard Miller, Executive Officer, FIC, National Institutes of Health. [FR Doc. 06–5883 Filed 6–29–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: rwilkins on PROD1PC63 with NOTICES_1 SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. A New Mouse Monoclonal Antibody Against Human Microphthalmia Transcription Factor (MITF) Description of Technology: Micropthalmia Transcription Factor (MITF) plays an important role in melanocyte development and melanoma growth. MlTF is important for embryonic development, regulating the generation of pigment cells and formation of melanomas and other tumors. MITF is made in various VerDate Aug<31>2005 16:30 Jun 29, 2006 Jkt 208001 isoforms that may play unique roles for different organs during different developmental periods. Additionally, tissue MITF levels can serve as a molecular marker for the diagnosis of metastatic melanoma and therapeutic response. This technology involves the generation of several novel mouse monoclonal antibodies against a subdomain of an MITF fragment that is cleaved during cell death. Importantly, these antibodies cross-react with human MITF. The antibody was raised by immunizing mice that are incapable of producing the MITF sub-domain used as the antigen. Three (3) different ‘‘clones’’ of these antibodies are currently available and their corresponding hybridoma names are 6A5 (IgG1), 1D2 (IgG2a) and 3D1 (IgG2a). Applications: (1) Novel mouse monoclonal antibodies specific to a domain of MITF as research material; (2) Novel mouse monoclonal antibodies that cross react with human MITF. Market: The currently commercially available MITF monoclonal antibodies recognize a particular domain of MITF. These have been made available by several companies including Neomarkers, Abcam, Biomeda Corporation, and Calbiochem. This antibody reacts with a different sub-domain of MITF and cross reacts with human MITF. Development Status: The technology is ready for the market. Inventors: Dr. Heinz Arnheiter, Mr. Wenfang Liu and Dr. Hideki Murakami. Relevant Publications Related to MITF: 1. LA Garraway, HR Widlund, MA Rubin, G Getz, AJ Berger, S Ramaswamy, R Beroukhim, DA Milner, SR Granter, J Du, C Lee, SN Wagner, C Li, TR Golub, DL Rimm, ML Meyerson, DE Fisher, WR Sellers. ‘‘Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.’’ Nature 2005 Jul 7;436(7047):117–122. 2. SR Granter, KN Weilbaecher, C Quigley, DE Fisher. ‘‘Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma.’’ Appl Immunohistochem Mol Morphol. 2002 Mar; 10(1):47–51. Patent Status: HHS Reference No. E– 228–2006/0—Research Material Availability: The inventor is no longer accepting requests for the antibody; it will now be solely available via a Biological Material License (BML). Licensing Contact: David A. Lambertson, PhD.; 301/435–4632; lambertsond@od.nih.gov. PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 Diamidine Inhibitors of Tdp1 as AntiCancer Agents Description of Technology: Available for licensing and commercial development are methods and compositions for treating cancer, using novel compounds derived from diamidine. Diamidine and its derivatives are potent inhibitors of tyrosyl-DNA-phosphodiesterase (Tdp1), which may be useful in chemotherapy. Camptothecins are effective Topoisomerase I (Top1) inhibitors, and two derivatives (Topotecan and Camptosar) are currently approved for treatment of ovarian and colorectal cancer. Camptothecins damage DNA by trapping covalent complexes between the Top1 catalytic tyrosine and the 3’end of the broken DNA. Tdp1 repairs Top1-DNA covalent complexes by hydrolyzing the tyrosyl-DNA bond. Thus, the presence and activity of Tdp1 can reduce the effectiveness of camptothecins as anti-cancer agents. In addition, Tdp1 repairs free-radicalmediated DNA breaks. Inhibition of Tdp1 using diamidine or its derivatives, may reduce repair of DNA breaks and increase the rate of apoptosis in cancer cells. In addition, diamidine derivatives have the potential to enhance the anti-neoplastic activity of Top1 inhibitors, by reducing repair of Top1-DNA lesions through inhibition of Tdp1. Development Status: Pre-clinical stage. Inventors: Yves Pommier and Christophe Marchand (NCI). Publications: 1. Z Liao et al. ‘‘Inhibition of human Tyrosyl-DNA Phosphodiesterase (Tdp1) by aminoglycoside antibiotics and ribosome inhibitors.’’ Mol Pharmacol. 2006 Apr 17; Epub ahead of print, doi:10.1124/mol.105.021865. 2. Y Pommier. ‘‘Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.’’ Curr Med Chem Anticancer Agents. 2004 Sep; 4(5):429– 34. Review. 3. Y Pommier et al. ‘‘Repair of and checkpoint response to topoisomerase I mediated DNA damage.’’ Mutat Res. 2003 Nov 27;532(1–2):173–203. Review. Patent Status: U.S. Provisional Application No. 60/786,604 filed 27 Mar 2006 (HHS Reference No. E–165–2006/ 0-US–01). Licensing Status: Available for nonexclusive or exclusive licensing. Licensing Contact: David A. Lambertson, PhD.; 301/435–4632; lambertsond@od.nih.gov. E:\FR\FM\30JNN1.SGM 30JNN1 Federal Register / Vol. 71, No. 126 / Friday, June 30, 2006 / Notices rwilkins on PROD1PC63 with NOTICES_1 Collaborative Research Opportunity: The Laboratory of Molecular Pharmacology at the National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize diamidine derivatives, particularly optimizing them for therapeutic use. Please contact Lisa Finkelstein at 301/451–7458 for more information. Use of Tetracyclines as Anti-Cancer Agents Description of Technology: The invention describes compositions of tetracycline compounds and their derivatives as having anticancer activity, as well as methods of treating cancer. Tetracyclines are commonly used as antibiotics; however, testing of these compounds in a high throughput screening system revealed certain derivatives to be potent inhibitors of tyrosyl-DNA-phosphodiesterase (Tdp1). Camptothecins are effective Topoisomerase I (Top1) inhibitors, and two derivatives (Topotecan and Camptosar) are currently approved for treatment of ovarian and colorectal cancer. Camptothecins damage DNA by trapping covalent complexes between the Top1 catalytic tyrosine and the 3’end of the broken DNA. Tdp1 repairs Top1-DNA covalent complexes by hydrolyzing the tyrosyl-DNA bond. This can reduce the effectiveness of camptothecins as anti-cancer agents. In addition, Tdp1 repairs free-radicalmediated DNA breaks. As disclosed in the instant technology, tetracyclines have the potential to enhance the anti-neoplastic activity of Top1 inhibitors by reducing repair of Top1-DNA lesions through inhibition of Tdp1. Inhibition of Tdp1 may also reduce repair of DNA breaks and increase the rate of apoptosis in cancer cells, making them potential anti-cancer agents on their own. Development Status: Pre-clinical stage. Inventors: Yves Pommier (NCI), Christophe Marchand (NCI), Laurent Thibaut (NCI). Publications: 1. Z Liao et al. ‘‘Inhibition of human Tyrosyl-DNA Phosphodiesterase (Tdp1) by aminoglycoside antibiotics and ribosome inhibitors.’’ Mol Pharmacol. 2006 Apr 17; Epub ahead of print, doi:10.1124/mol.105.021865. 2. Y Pommier. ‘‘Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle VerDate Aug<31>2005 16:30 Jun 29, 2006 Jkt 208001 checkpoints.’’ Curr Med Chem Anticancer Agents. 2004 Sep; 4(5):429– 34. Review. 3. Y Pommier et al. ‘‘Repair of and checkpoint response to topoisomerase I mediated DNA damage.’’ Mutat Res. 2003 Nov 27;532(1–2):173–203. Review. Patent Status: U.S. Provisional Application No. 60/786,746 filed 27 Mar 2006 (HHS Reference No. E–097–2006/ 0-US–01). Licensing Status: Available for nonexclusive or exclusive licensing. Licensing Contact: David A. Lambertson, PhD.; 301/435–4632; lambertsond@od.nih.gov. Collaborative Research Opportunity: The Laboratory of Molecular Pharmacology at the National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize tetracycline derivatives, particularly optimizing them for therapeutic use. Please contact Lisa Finkelstein at 301/451–7458 for more information. Dated: June 23, 2006. David R. Sadowski, Acting Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 06–5882 Filed 6–29–06; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6). Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Mental Health Special Emphasis Panel, Cooperative Drug Development Group For The Treatment Of Mental Illness. Date: July 11, 2006. PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 37587 Time: 10 a.m. to 12 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Yong Yao, PhD, Scientific Review Administrator, Division of Extramural Activities National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6149, MSC 9606, Bethesda, MD 20892–9606. 301–443–6102. yaoy3@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Mental Health Special Emphasis Panel, Rapid Assessment Post-Impact of Disaster. Date: July 11, 2006. Time: 3 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Tracy Waldeck, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6132, MSC 9608, Bethesda, MD 20852–9609. (301) 435–0322. waldeckt@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Mental Health Special Emphasis Panel, MLSCN Assay Review. Date: July 20, 2006. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815. Contact Person: Yong Yao, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6149, MSC 9606, Bethesda, MD 20892–9606, (301) 443–6102. yaoy3@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Mental Health Special Emphasis Panel; Mood/Anxiety Research Review. Date: July 24, 2006. Time: 1 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Christopher S. Sarampote, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, E:\FR\FM\30JNN1.SGM 30JNN1

Agencies

[Federal Register Volume 71, Number 126 (Friday, June 30, 2006)]
[Notices]
[Pages 37586-37587]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-5882]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

A New Mouse Monoclonal Antibody Against Human Microphthalmia 
Transcription Factor (MITF)

    Description of Technology: Micropthalmia Transcription Factor 
(MITF) plays an important role in melanocyte development and melanoma 
growth. MlTF is important for embryonic development, regulating the 
generation of pigment cells and formation of melanomas and other 
tumors. MITF is made in various isoforms that may play unique roles for 
different organs during different developmental periods. Additionally, 
tissue MITF levels can serve as a molecular marker for the diagnosis of 
metastatic melanoma and therapeutic response.
    This technology involves the generation of several novel mouse 
monoclonal antibodies against a sub-domain of an MITF fragment that is 
cleaved during cell death. Importantly, these antibodies cross-react 
with human MITF. The antibody was raised by immunizing mice that are 
incapable of producing the MITF sub-domain used as the antigen. Three 
(3) different ``clones'' of these antibodies are currently available 
and their corresponding hybridoma names are 6A5 (IgG1), 1D2 (IgG2a) and 
3D1 (IgG2a).
    Applications: (1) Novel mouse monoclonal antibodies specific to a 
domain of MITF as research material; (2) Novel mouse monoclonal 
antibodies that cross react with human MITF.
    Market: The currently commercially available MITF monoclonal 
antibodies recognize a particular domain of MITF. These have been made 
available by several companies including Neomarkers, Abcam, Biomeda 
Corporation, and Calbiochem.
    This antibody reacts with a different sub-domain of MITF and cross 
reacts with human MITF.
    Development Status: The technology is ready for the market.
    Inventors: Dr. Heinz Arnheiter, Mr. Wenfang Liu and Dr. Hideki 
Murakami.
    Relevant Publications Related to MITF:
    1. LA Garraway, HR Widlund, MA Rubin, G Getz, AJ Berger, S 
Ramaswamy, R Beroukhim, DA Milner, SR Granter, J Du, C Lee, SN Wagner, 
C Li, TR Golub, DL Rimm, ML Meyerson, DE Fisher, WR Sellers. 
``Integrative genomic analyses identify MITF as a lineage survival 
oncogene amplified in malignant melanoma.'' Nature 2005 Jul 
7;436(7047):117-122.
    2. SR Granter, KN Weilbaecher, C Quigley, DE Fisher. ``Role for 
microphthalmia transcription factor in the diagnosis of metastatic 
malignant melanoma.'' Appl Immunohistochem Mol Morphol. 2002 Mar; 
10(1):47-51.
    Patent Status: HHS Reference No. E-228-2006/0--Research Material
    Availability: The inventor is no longer accepting requests for the 
antibody; it will now be solely available via a Biological Material 
License (BML).
    Licensing Contact: David A. Lambertson, PhD.; 301/435-4632; 
lambertsond@od.nih.gov.

Diamidine Inhibitors of Tdp1 as Anti-Cancer Agents

    Description of Technology: Available for licensing and commercial 
development are methods and compositions for treating cancer, using 
novel compounds derived from diamidine. Diamidine and its derivatives 
are potent inhibitors of tyrosyl-DNA-phosphodiesterase (Tdp1), which 
may be useful in chemotherapy.
    Camptothecins are effective Topoisomerase I (Top1) inhibitors, and 
two derivatives (Topotecan[supreg] and Camptosar[supreg]) are currently 
approved for treatment of ovarian and colorectal cancer. Camptothecins 
damage DNA by trapping covalent complexes between the Top1 catalytic 
tyrosine and the 3'-end of the broken DNA. Tdp1 repairs Top1-DNA 
covalent complexes by hydrolyzing the tyrosyl-DNA bond. Thus, the 
presence and activity of Tdp1 can reduce the effectiveness of 
camptothecins as anti-cancer agents. In addition, Tdp1 repairs free-
radical-mediated DNA breaks.
    Inhibition of Tdp1 using diamidine or its derivatives, may reduce 
repair of DNA breaks and increase the rate of apoptosis in cancer 
cells. In addition, diamidine derivatives have the potential to enhance 
the anti-neoplastic activity of Top1 inhibitors, by reducing repair of 
Top1-DNA lesions through inhibition of Tdp1.
    Development Status: Pre-clinical stage.
    Inventors: Yves Pommier and Christophe Marchand (NCI).
    Publications:
    1. Z Liao et al. ``Inhibition of human Tyrosyl-DNA 
Phosphodiesterase (Tdp1) by aminoglycoside antibiotics and ribosome 
inhibitors.'' Mol Pharmacol. 2006 Apr 17; Epub ahead of print, 
doi:10.1124/mol.105.021865.
    2. Y Pommier. ``Camptothecins and topoisomerase I: a foot in the 
door. Targeting the genome beyond topoisomerase I with camptothecins 
and novel anticancer drugs: importance of DNA replication, repair and 
cell cycle checkpoints.'' Curr Med Chem Anticancer Agents. 2004 Sep; 
4(5):429-34. Review.
    3. Y Pommier et al. ``Repair of and checkpoint response to 
topoisomerase I mediated DNA damage.'' Mutat Res. 2003 Nov 27;532(1-
2):173-203. Review.
    Patent Status: U.S. Provisional Application No. 60/786,604 filed 27 
Mar 2006 (HHS Reference No. E-165-2006/0-US-01).
    Licensing Status: Available for non-exclusive or exclusive 
licensing.
    Licensing Contact: David A. Lambertson, PhD.; 301/435-4632; 
lambertsond@od.nih.gov.

[[Page 37587]]

    Collaborative Research Opportunity: The Laboratory of Molecular 
Pharmacology at the National Cancer Institute is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate, or commercialize diamidine 
derivatives, particularly optimizing them for therapeutic use. Please 
contact Lisa Finkelstein at 301/451-7458 for more information.

Use of Tetracyclines as Anti-Cancer Agents

    Description of Technology: The invention describes compositions of 
tetracycline compounds and their derivatives as having anticancer 
activity, as well as methods of treating cancer. Tetracyclines are 
commonly used as antibiotics; however, testing of these compounds in a 
high throughput screening system revealed certain derivatives to be 
potent inhibitors of tyrosyl-DNA-phosphodiesterase (Tdp1).
    Camptothecins are effective Topoisomerase I (Top1) inhibitors, and 
two derivatives (Topotecan[supreg] and Camptosar[supreg]) are currently 
approved for treatment of ovarian and colorectal cancer. Camptothecins 
damage DNA by trapping covalent complexes between the Top1 catalytic 
tyrosine and the 3'-end of the broken DNA. Tdp1 repairs Top1-DNA 
covalent complexes by hydrolyzing the tyrosyl-DNA bond. This can reduce 
the effectiveness of camptothecins as anti-cancer agents. In addition, 
Tdp1 repairs free-radical-mediated DNA breaks.
    As disclosed in the instant technology, tetracyclines have the 
potential to enhance the anti-neoplastic activity of Top1 inhibitors by 
reducing repair of Top1-DNA lesions through inhibition of Tdp1. 
Inhibition of Tdp1 may also reduce repair of DNA breaks and increase 
the rate of apoptosis in cancer cells, making them potential anti-
cancer agents on their own.
    Development Status: Pre-clinical stage.
    Inventors: Yves Pommier (NCI), Christophe Marchand (NCI), Laurent 
Thibaut (NCI).
    Publications:
    1. Z Liao et al. ``Inhibition of human Tyrosyl-DNA 
Phosphodiesterase (Tdp1) by aminoglycoside antibiotics and ribosome 
inhibitors.'' Mol Pharmacol. 2006 Apr 17; Epub ahead of print, 
doi:10.1124/mol.105.021865.
    2. Y Pommier. ``Camptothecins and topoisomerase I: a foot in the 
door. Targeting the genome beyond topoisomerase I with camptothecins 
and novel anticancer drugs: importance of DNA replication, repair and 
cell cycle checkpoints.'' Curr Med Chem Anticancer Agents. 2004 Sep; 
4(5):429-34. Review.
    3. Y Pommier et al. ``Repair of and checkpoint response to 
topoisomerase I mediated DNA damage.'' Mutat Res. 2003 Nov 27;532(1-
2):173-203. Review.
    Patent Status: U.S. Provisional Application No. 60/786,746 filed 27 
Mar 2006 (HHS Reference No. E-097-2006/0-US-01).
    Licensing Status: Available for non-exclusive or exclusive 
licensing.
    Licensing Contact: David A. Lambertson, PhD.; 301/435-4632; 
lambertsond@od.nih.gov.
    Collaborative Research Opportunity: The Laboratory of Molecular 
Pharmacology at the National Cancer Institute is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate, or commercialize tetracycline 
derivatives, particularly optimizing them for therapeutic use. Please 
contact Lisa Finkelstein at 301/451-7458 for more information.

    Dated: June 23, 2006.
David R. Sadowski,
Acting Director, Division of Technology Development and Transfer, 
Office of Technology Transfer, National Institutes of Health.
[FR Doc. 06-5882 Filed 6-29-06; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.